Significant Ownership of MPM BioImpact LLC
- Signature - Title
- Christopher Wolf - Chief Financial Officer
- Location
- Boston, MA
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by MPM BioImpact LLC.
Follow Filing Activity
Follow MPM BioImpact LLC and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from MPM BioImpact LLC
Significant Ownership of MPM BioImpact LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| CNTX | Context Therapeutics Inc. | Common Stock, par value $0.001 per share | 12% | $15,698,705 | -$5,918,942 | 10,679,391 | -27% | MPM BioImpact LLC | 31 Dec 2025 |
| DBVT | DBV TECHNOLOGIES S.A. | Ordinary Shares, nominal value 0.10 euro per share | 8.8% | $577,119,085 | +$32,933,228 | 26,066,806 | +6.1% | MPM BioImpact LLC | 31 Mar 2026 |
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 7.2% | 1,000,682 | MPM BioImpact LLC | 31 Mar 2026 | |||
| CLYM | Climb Bio, Inc. | Common Stock, par value $0.0001 per share | 5.6% | $13,437,544 | 2,671,480 | MPM BioImpact LLC | 31 Dec 2025 | ||
| CMPX | Compass Therapeutics, Inc. | Common Stock, par value $0.001 per share | 4.1% | $15,180,764 | -$7,952,556 | 5,622,505 | -34% | MPM BioImpact LLC | 30 Jun 2025 |
Schedules 13D/G Reported by MPM BioImpact LLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.